LEP and breast cancer: Hence, HNK has demonstrated a protective effect on breast cancer in a diet-induced-obese mouse model with high leptin levels and could serve as a new endocrine therapy drug for patients with obesity-related breast cancer accompanied by negative estrogen and progesterone receptors; however, the research described above was limited to animal experiments, and further evidence in humans is required, thus clinical trials are warranted to further investigate HNK.